Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Ressurecting Sun...

    Ressurecting Sun Pharma: Shanghvi committed to pharma business; surrenders NBFC licence

    Meghna A SinghaniaWritten by Meghna A Singhania Published On 2019-05-29T14:37:02+05:30  |  Updated On 16 Aug 2021 10:33 AM IST

    New Delhi: The billionaire entrepreneur, Dilip Shanghvi, founder of the 1983 established drug giant Sun Pharmaceuticals (Sun Pharma) is striving to bounce back. Shanghvi is now determined to focus and remain committed to the pharma business as his personal investment company, Shanghvi Finance Private Limited (SFPl) has surrendered its nonbanking finance company (NBFC) licence, suggests a media report.


    The company had submitted its application to surrender the NBFC licence in the month of March, according to a recent media report.


    Medical Dialogue had earlier reported that after a four-year decline that erased 65 per cent from the value of Sun Pharma Industries, Shanghvi was preparing to make a comeback. He was doing it by borrowing a page from Big Pharma's playbook: investing in higher-margin patented medicines rather than relying solely on copying drugs.


    Also Read: Dilip Shanghvi plans comeback; Sun Pharma to develop its own medicines: Report


    In 2015, the firm had become the third largest producer in the world in terms of volumes and was poised to grow into an industry of $20 billion. The pharma giant was once the most profitable and the largest pharmaceutical company in India by market capitalisation on the Indian exchanges. However, over the past few years, the company has taken a hit resulting in fall of its financial graph.


    Intermittently, the company was in soup over corporate governance concerns stemming from a whistleblower complaint, leading to a fall in its shares recently.


    The company endeavoured to control the damages done by incorporating measures including a change in the distribution strategy. Unfortunately, the decision proved a backfire as the company recently reported a tumble in its fourth-quarter profit comparatively falling by half.


    Also Read: Sun Pharma Q4 profit falls by half to Rs 636 crore due to change in distribution strategy


    However, Shanghvi is still making attempts to take control of the turbulence in his business, for this, the enterprenuer has decided not to diversify away from his commitment to the pharma business. Thereby, SFPl, the financial business under by the Shanghvi Group has reportedly surrendered the NBFC licence.


    Sanghvi holds 98.28% of SFPL, the major investments of which are in Sun Pharmaceutical and Sun Pharmaceutical Advanced Research--holding 40% in the first and 52% in the second.


    The market value of these investments was Rs 47,326 crore at the end of March. SFPL's total assets had amounted to Rs 72,436.31 crore at the end of FY18, according to rating agency CARE.


    SFPL has in the past stood guarantee for the fund-raising plans of related companies. In December, it gave an irreversible guarantee to Aditya Medisales' commercial paper worth Rs 500 crore and in March it backed fund-raising to the tune of Rs 500 crore by Suraksha Asset Reconstruction, a stressed asset buyout company owned by Sudhir Valia, a director in Sun Pharma and Shanghvi's brother-in-law.


    It is learnt through a report in Economic Times that SFPL, besides surrendering its licence was willing to convert it into a core investment company (CIC). A CIC is a non-banking financial company carrying on the business of acquisition of shares and securities and which holds not less than 90 per cent of its net assets in the form of investment in equity shares, preference shares, bonds, debentures, debt or loans in group companies and its investments in the equity shares in group companies constitutes not less than 60 per cent of its net assets as on the date of the last audited balance sheet.


    However, the company's proposal has not been cleared by the RBI, which has asked it to meet certain criteria.

    DermatologyDilip ShanghviFinancial BusinessFY18genericgeneric drugsmedicinesNBFCNBFC licencenonbanking finance companypatented medicinepharma businesspharma sectorpharmaceuticalRanbaxyRBIrevenueSEBISFPLShanghvi Finance Private LimitedShanghvi GroupSun PharmaSun Pharma GroupSun Pharma investment business
    Source : With inputs

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Meghna A Singhania
    Meghna A Singhania

      Meghna A Singhania is the founder and Editor-in-Chief at Medical Dialogues. An Economics graduate from Delhi University and a post graduate from London School of Economics and Political Science, her key research interest lies in health economics, and policy making in health and medical sector in the country. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok